Metastatic Melanoma
Showing 26 - 50 of 296
Metastatic Melanoma Trial run by the National Cancer Institute (NCI) (Aldesleukin, Fludarabine, Cyclophosphamide)
Completed
- Metastatic Melanoma
- Aldesleukin
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 21, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +20 more
- Ipilimumab
- +3 more
-
Tampa, Florida
- +6 more
Jan 13, 2023
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,
Active, not recruiting
- Metastatic Melanoma
- +6 more
- Ibrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 13, 2023
Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)
Recruiting
- Melanoma
- Metastatic Melanoma
- CDX-301
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 12, 2023
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma Trial in United
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +12 more
- Memantine
- +4 more
-
Tucson, Arizona
- +60 more
Jan 11, 2023
Metastatic Melanoma Trial in Tampa (procedure, drug, other)
Active, not recruiting
- Metastatic Melanoma
- Surgery
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center & Research Institute
Jan 10, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,
Recruiting
- Chronic Lymphocytic Leukemia
- +9 more
- BGB-10188
- +2 more
-
Adelaide, Australia
- +12 more
Jan 6, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma Trial in Rochester (Anti-PD-L1 Monoclonal Antibody
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +3 more
- Anti-PD-L1 Monoclonal Antibody IMC-001
- Punch Biopsy
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Dabrafenib
- MEK-1/MEKK-1 Inhibitor E6201
-
Scottsdale, Arizona
- +2 more
Jan 4, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial in Canada,
Active, not recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +20 more
- Pembrolizumab
- Ziv-Aflibercept
-
Tampa, Florida
- +8 more
Jan 3, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Tumor Trial in
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Dabrafenib
- +4 more
-
Phoenix, Arizona
- +48 more
Jan 3, 2023
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Jacksonville (drug,
Active, not recruiting
- Metastatic Melanoma
- +3 more
- Imiquimod
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Jan 3, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Melanoma Trial in Columbus
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Natural Killer Cell Therapy
- Temozolomide
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Dec 28, 2022
Metastatic Melanoma, Metastatic Breast Cancer, Advanced Renal Cell Carcinoma Trial in Worldwide (single arm)
Withdrawn
- Metastatic Melanoma
- +5 more
- single arm
- (no location specified)
Dec 20, 2022
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, NSCLC Trial in Worldwide (Lifileucel, LN-145, Pembrolizumab)
Recruiting
- Metastatic Melanoma
- +2 more
- Lifileucel
- +5 more
-
La Jolla, California
- +44 more
Dec 16, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Tumor in the Brain Trial in
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +6 more
- Ipilimumab
- +4 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 12, 2022
Immunotherapy in Patients With Metastatic Melanoma
Not yet recruiting
- Metastatic Melanoma
- data collection
- (no location specified)
Nov 28, 2022
Advanced Malignant Solid Tumor, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Recruiting
- Advanced Malignant Solid Neoplasm
- +28 more
- Capecitabine
- +16 more
-
Conroe, Texas
- +4 more
Dec 5, 2022
Unresectable Melanoma, Metastatic Melanoma Trial in Brussel, Amsterdam, Barcelona (NEO-PTC-01)
Recruiting
- Unresectable Melanoma
- Metastatic Melanoma
- NEO-PTC-01
-
Brussel, Belgium
- +2 more
Dec 5, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
- Dabrafenib Mesylate
- +2 more
-
Atlanta, Georgia
- +6 more
Nov 30, 2022
Metastatic Melanoma Trial in Netherlands (drug, device, procedure)
Terminated
- Metastatic Melanoma
- Vemurafenib plus cobimetinib
- +3 more
-
Amsterdam, Netherlands
- +9 more
Nov 24, 2022
Advanced Melanoma, Metastatic Melanoma Trial in Saint Louis (Memory-like natural killer cells, Relatilmab, Nivolumab)
Not yet recruiting
- Advanced Melanoma
- Metastatic Melanoma
- Memory-like natural killer cells
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Nov 16, 2022
Unresectable Melanoma, Metastatic Melanoma, Stage III NSCLC Trial in Louisville, New York (IOV-4001)
Recruiting
- Unresectable Melanoma
- +3 more
- IOV-4001
-
Louisville, Kentucky
- +2 more
Nov 21, 2022
Immunotherapy Among BRAF-Positive Melanoma Patients Treated in
Completed
- Metastatic Melanoma
- Nivolumab
- +5 more
-
East Hanover, New JerseyNovartis Investigative Site
Nov 11, 2022